These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2950906)

  • 1. Biological properties of HTLV-III/LAV: a possible pathway of natural infection in vivo.
    Popovic M; Read-Connole E; Gartner S
    Ann Inst Pasteur Immunol; 1986; 137D(3):413-7. PubMed ID: 2950906
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.
    Sodroski J; Goh WC; Rosen C; Campbell K; Haseltine WA
    Nature; 1986 Jul 31-Aug 6; 322(6078):470-4. PubMed ID: 3016552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HTLV-III/LAV and the origin and pathogenesis of AIDS.
    Gallo RC; Robert-Guroff M; Wong-Staal F; Reitz MS; Arya SK; Streicher HZ
    Int Arch Allergy Appl Immunol; 1987; 82(3-4):471-5. PubMed ID: 3032803
    [No Abstract]   [Full Text] [Related]  

  • 4. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.
    McDougal JS; Mawle A; Cort SP; Nicholson JK; Cross GD; Scheppler-Campbell JA; Hicks D; Sligh J
    J Immunol; 1985 Nov; 135(5):3151-62. PubMed ID: 2995487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Is the HTLV III/LAV virus the causative agent of AIDS or merely an agent of one of the opportunistic infections?].
    Hollán Z
    Orv Hetil; 1986 Dec; 127(52):3219-20. PubMed ID: 2949193
    [No Abstract]   [Full Text] [Related]  

  • 6. Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses.
    Margolick JB; Volkman DJ; Folks TM; Fauci AS
    J Immunol; 1987 Mar; 138(6):1719-23. PubMed ID: 3493285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UV light exposure and HIV replication.
    Clerici M; Shearer GM
    Science; 1992 Nov; 258(5085):1070-1. PubMed ID: 1439812
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms of immune suppression in AIDS: possibilities of prevention.
    Gluckman JC; Klatzmann D
    Cancer Detect Prev; 1988; 12(1-6):175-80. PubMed ID: 3052831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of the human T-lymphotropic retroviruses and the role of HTLV-III/LAV in AIDS.
    Gurgo C; Robert-Guroff M; Gallo RC
    Antibiot Chemother (1971); 1987; 38():1-12. PubMed ID: 2821878
    [No Abstract]   [Full Text] [Related]  

  • 10. [Physio-pathogenesis of the acquired immunodeficiency syndrome].
    Gamba G; Sifuentes J; Ruiz-Palacios GM
    Rev Invest Clin; 1987; 39 Suppl():13-7. PubMed ID: 2967531
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of HTLV-III/LAV antigens in peripheral blood lymphocytes from patients with AIDS.
    Pekovic DD; Chausseau JP; Lapointe N; Michaud J; Garzon S; Strykowski H; Tsoukas C; Gilmore N; Goldman H; Gornitsky M
    Arch Virol; 1986; 91(1-2):11-9. PubMed ID: 3092784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphadenopathy-associated-virus infection and acquired immunodeficiency syndrome.
    Gluckman JC; Klatzmann D; Montagnier L
    Annu Rev Immunol; 1986; 4():97-117. PubMed ID: 3011034
    [No Abstract]   [Full Text] [Related]  

  • 13. Epidermal Langerhans cells--a target for HTLV-III/LAV infection.
    Tschachler E; Groh V; Popovic M; Mann DL; Konrad K; Safai B; Eron L; diMarzo Veronese F; Wolff K; Stingl G
    J Invest Dermatol; 1987 Feb; 88(2):233-7. PubMed ID: 3100656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inhibition of infectivity of HTLV-III in vitro.
    Mitsuya H; Matsushita S; Harper ME; Broder S
    Cancer Res; 1985 Sep; 45(9 Suppl):4583s-4587s. PubMed ID: 2990689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and immunological findings in HTLV-III infection.
    Krohn KJ; Antonen J; Valle SL; Kazakevicius R; Saxinger C; Gallo RC; Ranki A
    Cancer Res; 1985 Sep; 45(9 Suppl):4612s-4615s. PubMed ID: 2990694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
    Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
    J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective reduction of the OKT 4 positive 4B4 positive subset during HTLV III infection in humans.
    De Paoli P; Battistin S; Reitano M; Crovatto M; Tirelli U; Diodato S; Santini G
    J Clin Lab Immunol; 1987 Mar; 22(3):117-9. PubMed ID: 3112401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential ability of human immunodeficiency virus isolates to productively infect human cells.
    Evans LA; McHugh TM; Stites DP; Levy JA
    J Immunol; 1987 May; 138(10):3415-8. PubMed ID: 3106482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of cytotoxic T lymphocyte responses to influenza and antibodies to human T lymphotropic virus-III in homosexual men. Selective loss of an influenza-specific, human leukocyte antigen-restricted cytotoxic T lymphocyte response in human T lymphotropic virus-III positive individuals with symptoms of acquired immunodeficiency syndrome and in a patient with acquired immunodeficiency syndrome.
    Shearer GM; Salahuddin SZ; Markham PD; Joseph LJ; Payne SM; Kriebel P; Bernstein DC; Biddison WE; Sarngadharan MG; Gallo RC
    J Clin Invest; 1985 Oct; 76(4):1699-704. PubMed ID: 2997287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lymphopathic HTLV-III-LAV infection and acquired immunodeficiency syndrome].
    Pokrovskiĭ VV
    Ter Arkh; 1986; 58(10):151-4. PubMed ID: 3541273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.